Reported Earlier, Savara Announces $130M Public Offering Including 23.8M Shares And 7.1M Pre-Funded Warrants Priced At $4.20 Per Share
Benzinga Newsdesk 1 year ago
News
Savara intends to use the proceeds from the offering for general corporate purposes, which include the funding of clinical development of and pursuing regulatory approval for MOLBREEVI*, investing in
Savara intends to use the proceeds from the offering for general corporate purposes, which include the funding of clinical development of and pursuing regulatory approval for MOLBREEVI*, investing in commercialization infrastructure and supply, commercial launch preparation activities in the United States and European Union, and general and administrative expenses.